Changes in accounting policies - Lenzing Annual Report 2022

The accounting policies applied by the Lenzing Group in 2022 remained unchanged in comparison with the previous financial year, with the exception of the changes described in this section.

Mandatory changes in accounting policies

The following new and amended standards and interpretations were adopted into EU law and required mandatory application by the Lenzing Group beginning with the 2022 financial year:

Standards/interpretations		Publication by the IASB	Mandatory application according to IASB for financial years from	Adopted by the EU as at 31/12/2022
IFRS 3	References to the Conceptual Framework	14/05/2020	01/01/2022	yes
IAS 16	Property, plant and equipment – Proceeds before intended use	14/05/2020	01/01/2022	yes
IAS 37	Onerous contracts – Cost of fulfilling a contract	14/05/2020	01/01/2022	yes
Various	Annual Improvements of IFRSs 2018-2020	14/05/2020	01/01/2022	yes

The new or amended standards and interpretations applicable as of January 1, 2022 did not result in any significant changes to the consolidated financial statements of the Lenzing Group.

The following new or amended standards and interpretations had been published by the IASB prior to the preparation of these consolidated financial statements, but did not require mandatory application by the Lenzing Group for financial years beginning on or before January 1, 2022:

Standards/interpretations

Publication by the IASB

Mandatory application according to IASB for financial years from

Adopted by the EU as at 31/12/2022

IFRS 10, IAS 28

Sale or contribution of assets between an investor and its associate or joint venture

11/09/2014

unknown¹

IFRS 14

Regulatory Deferral Accounts

30/01/2014

01/01/2016

no²

IFRS 16

Lease Liability in a Sale and Leaseback

22/09/2022

01/01/2024

IFRS 17

Insurance Contracts

18/05/2017

01/01/2023

yes

IFRS 17

Initial Application of IFRS 17 and IFRS 9 – Comparative Information

09/12/2021

01/01/2023

yes

IAS 1

Classification of liabilities as current or non-current

23/01/2020

01/01/2024

IAS 1

Classification of debt with covenants as current or non-current

31/10/2022

01/01/2024

IAS 1

Disclosure of Accounting Policies

12/02/2021

01/01/2023

yes

IAS 8

Definition of Accounting Estimates

12/02/2021

01/01/2023

yes

IAS 12

Deferred Tax related to Assets and Liabilities arising from a Single Transaction

07/05/2021

01/01/2023

yes

1)	The IASB has deferred the effective date of this standard indefinitely.
2)	The European Commission does not recommend the adoption of interim standard IFRS 14 into EU law at the present time.

The other above-mentioned new or amended standards and interpretations were not adopted prematurely by the Lenzing Group. They are either not relevant for the Group or do not have a material impact on the earnings, assets or liabilities and the cash flows of the Lenzing Group.

The application of these standards and interpretations is generally planned following their endorsement by the EU.

Voluntary changes in accounting policies

No voluntary changes to accounting policies were applied in the 2022 financial year.

Since the beginning of the 2021 financial year, the Lenzing Group has reported its consolidated income statement applying the cost of sales method. The previous presentation was according to the nature of expense method. The modification in the presentation of the income statement aims to enhance the international comparability of the Lenzing Group’s consolidated income statement. As part of this transition, some amounts previously affecting EBIT/EBITDA were reclassified to the financial result (capitalized borrowing costs for the production of non-current assets amounting to EUR 21,166 thousand in 2021, 2020: EUR 8,429 thousand, net interest from defined benefit plans of EUR minus 1,757 thousand in 2021, 2020: EUR minus 2,144 thousand, and loan commitment fees of EUR minus 2,432 thousand in 2021, 2020: EUR minus 2,033 thousand). All amounts were adjusted retrospectively. The Lenzing Group’s performance continues to be measured by EBITDA (earnings before interest, tax, depreciation on property, plant and equipment and right-of-use assets and amortization of intangible assets and before income from the release of investment grants) (see note 4 for reconciliation). The following table shows the reconciliation from the nature of expense method to the cost of sales method:

Reconciliation from nature of expense method to cost of goods sold method
EUR '000
2021	Consolidated Income Statement – Cost of goods sold method	Revenue	Change in inventories of finished goods and work in progress	Own work capitalized	Other operating income	Gains or losses from the fair value measurement of biological assets	Cost of material and other purchased services	Personnel expenses	Other operating expenses	Amortization of intangible assets and depreciation of property, plant and equipment and right-of-use assets	Income from the release of investment grants	Earnings before interest and tax (EBIT)
Consolidated Income Statement – Nature of expense method		2,194,624	54,587	56,938	78,026	2,258	(1,203,153)	(452,617)	(367,721)	(164,269)	1,944	200,615
Revenue	2,194,624	2,194,624
Cost of sales	(1,692,760)		54,587	56,938		2,258	(1,198,921)	(329,344)	(128,984)	(151,118)	1,825
Gross profit	501,864

Other operating income	78,026				78,026
Selling expenses	(233,981)						(1,575)	(41,619)	(186,684)	(4,103)
Administrative expenses	(117,547)						(1,333)	(68,632)	(39,592)	(8,100)	112
Research and development expenses	(23,993)						(1,324)	(13,021)	(8,707)	(948)	7
Other operating expenses	(3,753)								(3,753)
Earnings before interest and tax (EBIT)	200,615

Reconciliation from nature of expense method to cost of goods sold method

EUR '000

2020

Consolidated Income Statement – Cost of goods sold method

Revenue

Change in inventories of finished goods and work in progress

Own work capitalized

Other operating income

Gains or losses from the fair value measurement of biological assets

Cost of material and other purchased services

Personnel expenses

Other operating expenses

Amortization of intangible assets and depreciation of property, plant and equipment and right-of-use assets

Income from the release of investment grants

Earnings before interest and tax (EBIT)

Consolidated Income Statement – Nature of expense method

1,632,607

(41,299)

52,080¹

59,145¹

(10,334)

(898,392)

(353,609)¹

(247,872)¹

(160,448)

1,979

33,858

Revenue

1,632,607

Cost of sales

(1,386,412)

(41,299)

52,080

(10,334)

(870,705)

(255,046)

(114,701)

(148,232)

1,825

Gross profit

246,195

Other operating income

59,145

Selling expenses

(156,932)

(1,249)

(32,717)

(119,300)

(3,721)

Administrative expenses

(88,236)

(25,847)

(57,904)

3,224

(7,808)

Research and development expenses

(16,181)

(455)

(7,942)

(7,098)

(687)

Other operating expenses

(10,133)

(136)

(9,997)

Earnings before interest and tax (EBIT)

33,858

1)	Reclassification of capitalized borrowing costs, net interest from defined benefit plans and commitment fees from EBIT/EBITDA to the financial result.

Letter from the
Chief Executive Officer

Note 2. Changes in accounting policies

Mandatory changes in accounting policies

Voluntary changes in accounting policies

Topics filter

Results for